CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Oncolytics Biotech Inc (USA) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Oncolytics Biotech Inc (USA)
1167 Kensington Cres Nw Suite 210
Calgary Alberta Canada T2n 1X7
Phone: (403) 670-7377p:403 670-7377 CALGARY, AB  T2R 0C5  Canada Ticker: ONCYONCY

Business Summary
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202312/31/2022YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Wayne F.Pisano 68 11/2/2016 5/9/2013
President, Chief Executive Officer, Director Matthew C.Coffey 1/19/2017 7/1/1999
Chief Financial Officer Kirk J.Look 1/1/2021 11/12/2012
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Oncolytics Biotech (Barbados) Inc.
Oncolytics Biotech (US) Inc.
ONCY
ONCYD
ONCYF

General Information
Number of Employees: 29 (As of 12/31/2022)
Outstanding Shares: 72,368,797 (As of 8/13/2023)
Shareholders: 199
Stock Exchange: NASD
Fax Number: (403) 283-0858
Email Address: dougballonc@aol.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, September 27, 2023